{"product_id":"wc-0efe51bcb5f34c14-50425","title":"George Washington University Hematology Update Symposium 2026","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003eGeorge Washington University Hematology Update Symposium 2026\u003c\/h1\u003e\r\n\u003ch2\u003eGeorge Washington University Hematology Update Symposium 2026 | Myeloproliferative Neoplasms, CMML, Multiple Myeloma, Coagulation Disorders, AML, CLL, Lymphoma \u0026amp; Bone Marrow Failure\u003c\/h2\u003e\r\nThe \u003cstrong\u003eGeorge Washington University Hematology Update Symposium 2026\u003c\/strong\u003e provides a comprehensive, evidence-based educational update on the latest diagnostic and therapeutic advances in malignant and nonmalignant hematology.\r\n\r\nOrganized by the \u003cstrong\u003eGW Cancer Center at The George Washington University School of Medicine and Health Sciences\u003c\/strong\u003e, this one-day educational symposium brings together nationally recognized experts in hematology, medical oncology, coagulation disorders, bone marrow diseases, and hematologic malignancies.\r\n\r\nHeld on February 28, 2026, at the Hyatt Regency Bethesda in Maryland, the program reviews major developments in myeloproliferative neoplasms, chronic myelomonocytic leukemia, multiple myeloma, coagulation disorders, acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma, and bone marrow failure syndromes.\r\n\r\nDirected by \u003cstrong\u003eRobert S. Siegel, MD\u003c\/strong\u003e, the symposium emphasizes translating contemporary clinical evidence, emerging treatments, and evolving hematology practice standards into practical patient management.\r\n\r\nThe \u003cstrong\u003eGW Hematology Update 2026\u003c\/strong\u003e curriculum combines disease-specific reviews, expert perspectives, and clinically relevant discussions to help healthcare professionals evaluate complex blood disorders and incorporate recent advances into everyday clinical practice.\r\n\u003ch2\u003eCourse Details\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e George Washington University Hematology Update Symposium 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial Event:\u003c\/strong\u003e 2026 Hematology Update Symposium\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOrganizer:\u003c\/strong\u003e The George Washington University School of Medicine and Health Sciences\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePresented By:\u003c\/strong\u003e GW Cancer Center\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse Director:\u003c\/strong\u003e Robert S. Siegel, MD\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eDate:\u003c\/strong\u003e Saturday, February 28, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLocation:\u003c\/strong\u003e Bethesda, Maryland, USA\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eVenue:\u003c\/strong\u003e Hyatt Regency Bethesda\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eVenue Address:\u003c\/strong\u003e One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial Event Format:\u003c\/strong\u003e Live, In-Person Symposium\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePrimary Specialty:\u003c\/strong\u003e Hematology\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAdditional Focus:\u003c\/strong\u003e Medical Oncology, Hematopathology, Internal Medicine, Coagulation Disorders and Bone Marrow Diseases\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial AMA CME:\u003c\/strong\u003e Up to 7.00 AMA PRA Category 1 Credits™\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eABIM MOC:\u003c\/strong\u003e Up to 7.00 MOC Points\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eScientific Lectures:\u003c\/strong\u003e 7\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAdditional Program Sessions:\u003c\/strong\u003e Welcome and Introduction; Closing Remarks\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial Participant Resources:\u003c\/strong\u003e Electronic Syllabus, PDF Slide Handouts and Archived Session Recordings\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe original GW educational activity provides eligible registered participants with access to educational materials and archived presentations through December 31, 2026, under the organizer's access policies.\r\n\r\nThese publisher-hosted resources and professional credits are separate from any files distributed through MedicalAmboss.\r\n\u003ch2\u003eTarget Audience\u003c\/h2\u003e\r\nThe symposium is intended for healthcare professionals involved in the diagnosis, treatment, and multidisciplinary management of hematologic conditions.\r\n\r\nThe target audience includes:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHematologists\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Oncologists\u003c\/li\u003e\r\n \t\u003cli\u003eHematopathologists\u003c\/li\u003e\r\n \t\u003cli\u003eInternal Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eHematology-Oncology Specialists\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Hematologists\u003c\/li\u003e\r\n \t\u003cli\u003eHospitalists\u003c\/li\u003e\r\n \t\u003cli\u003eOncology Nurses\u003c\/li\u003e\r\n \t\u003cli\u003eHematology Nurses\u003c\/li\u003e\r\n \t\u003cli\u003ePhysician Assistants\u003c\/li\u003e\r\n \t\u003cli\u003eNurse Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced Practice Providers\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Residents\u003c\/li\u003e\r\n \t\u003cli\u003eHematology and Oncology Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eAllied Healthcare Professionals\u003c\/li\u003e\r\n \t\u003cli\u003eOther Clinicians Involved in the Care of Patients With Blood Disorders\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program is especially relevant to clinicians seeking updates in hematologic malignancies, coagulation abnormalities, plasma cell disorders, and bone marrow failure syndromes.\r\n\u003ch2\u003eProgram Overview\u003c\/h2\u003e\r\nHematology continues to evolve rapidly as advances in molecular diagnostics, disease classification, targeted therapies, immunotherapy, and supportive care reshape the management of blood disorders.\r\n\r\nThe \u003cstrong\u003eGeorge Washington University Hematology Update Symposium 2026\u003c\/strong\u003e addresses these developments through a focused educational review of important hematologic conditions.\r\n\r\nThe program covers:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMyeloproliferative Neoplasms\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Myelomonocytic Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eMultiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003ePlasma Cell Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eCoagulation Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Myeloid Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Lymphocytic Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eLymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Failure\u003c\/li\u003e\r\n \t\u003cli\u003eHematologic Disease Classification\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular and Cytogenetic Testing\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eCurrent Treatment Strategies\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging Targeted Therapies\u003c\/li\u003e\r\n \t\u003cli\u003eImmunotherapeutic Approaches\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive Hematologic Care\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-Based Clinical Decision-Making\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe educational program integrates clinical research with practical diagnostic and management considerations relevant to hematology and oncology practice.\r\n\u003ch2\u003eLearning Objectives\u003c\/h2\u003e\r\nUpon successful participation in the original educational activity, participants should be better able to:\r\n\u003col start=\"1\" data-spread=\"true\"\u003e\r\n \t\u003cli\u003eDiscuss recent diagnostic and therapeutic advances in hematology, including developments affecting hematologic malignancies and nonmalignant blood disorders.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate contemporary scientific evidence involving malignant hematologic diseases, coagulation abnormalities, and bone marrow disorders.\u003c\/li\u003e\r\n \t\u003cli\u003eApply current clinical evidence, practice recommendations, and diagnostic tools to improve patient assessment and individualized treatment planning.\u003c\/li\u003e\r\n \t\u003cli\u003eFormulate evidence-based approaches to complex hematologic conditions, including leukemia, lymphoma, plasma cell malignancies, and bone marrow failure syndromes.\u003c\/li\u003e\r\n \t\u003cli\u003eReview developments in the diagnosis, classification, risk assessment, and management of myeloproliferative neoplasms and chronic myelomonocytic leukemia.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate evolving treatment strategies for multiple myeloma and related plasma cell disorders.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize common and complex coagulation abnormalities and consider appropriate diagnostic and therapeutic approaches.\u003c\/li\u003e\r\n \t\u003cli\u003eReview clinically important advances in acute myeloid leukemia and chronic lymphocytic leukemia.\u003c\/li\u003e\r\n \t\u003cli\u003eExamine contemporary diagnostic and treatment considerations for lymphoma.\u003c\/li\u003e\r\n \t\u003cli\u003eIdentify major categories of bone marrow failure and understand principles of clinical evaluation and treatment selection.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\nThe objectives above combine the stated course goals with educational themes reflected in the official program.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eOfficial Program Topics\u003c\/h1\u003e\r\n\u003ch2\u003eSaturday, February 28, 2026\u003c\/h2\u003e\r\n\u003cem\u003eAll times are Eastern Time (ET).\u003c\/em\u003e\r\n\u003ch2\u003eWelcome and Introduction\u003c\/h2\u003e\r\n\u003ch3\u003eWelcome | Introduction to Program\u003c\/h3\u003e\r\n\u003cstrong\u003e8:00 AM – 8:15 AM\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Robert S. Siegel, MD\r\n\r\n\u003cstrong\u003eProfessor of Medicine; Associate Center Director for Education and Training, The George Washington University, GW Cancer Center\u003c\/strong\u003e\r\n\r\nThe opening session introduces the symposium's educational focus on recent developments in hematology and the clinical application of new diagnostic and therapeutic evidence.\r\n\u003ch2\u003eSession I – Myeloid Neoplasms\u003c\/h2\u003e\r\n\u003ch3\u003eMyeloproliferative Neoplasms + CMML\u003c\/h3\u003e\r\n\u003cstrong\u003e8:15 AM – 9:15 AM\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Ayalew Tefferi, MD\r\n\r\n\u003cstrong\u003eBarbara Woodward Lips Professor of Medicine, Mayo Clinic\u003c\/strong\u003e\r\n\r\nThis presentation reviews clinically important developments involving myeloproliferative neoplasms and chronic myelomonocytic leukemia.\r\n\r\nMyeloproliferative neoplasms represent a group of clonal hematopoietic disorders characterized by abnormal production of one or more blood cell lineages.\r\n\r\nChronic myelomonocytic leukemia is a myeloid neoplasm with overlapping myelodysplastic and myeloproliferative features.\r\n\r\nImportant clinical considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMyeloproliferative Neoplasms\u003c\/li\u003e\r\n \t\u003cli\u003ePolycythemia Vera\u003c\/li\u003e\r\n \t\u003cli\u003eEssential Thrombocythemia\u003c\/li\u003e\r\n \t\u003cli\u003ePrimary Myelofibrosis\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Myelomonocytic Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eClonal Hematopoiesis\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular Mutations\u003c\/li\u003e\r\n \t\u003cli\u003eJAK2, CALR and MPL Mutations\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Classification\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eDisease Risk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eThrombotic Complications\u003c\/li\u003e\r\n \t\u003cli\u003eDisease Progression\u003c\/li\u003e\r\n \t\u003cli\u003eCurrent Treatment Approaches\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging Therapeutic Strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe session addresses disease-specific evaluation and the role of evolving scientific evidence in the management of myeloid neoplasms.\r\n\u003ch2\u003eSession II – Plasma Cell Disorders\u003c\/h2\u003e\r\n\u003ch3\u003eMultiple Myeloma\u003c\/h3\u003e\r\n\u003cstrong\u003e9:15 AM – 10:15 AM\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Kenneth Anderson, MD\r\n\r\n\u003cstrong\u003eKraft Family Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School\u003c\/strong\u003e\r\n\r\nThis session examines multiple myeloma, an important plasma cell malignancy associated with bone marrow infiltration, monoclonal protein production, and systemic complications.\r\n\r\nThe educational discussion relates to evolving diagnostic and treatment strategies for plasma cell disorders.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMultiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003ePlasma Cell Dyscrasias\u003c\/li\u003e\r\n \t\u003cli\u003eMonoclonal Gammopathies\u003c\/li\u003e\r\n \t\u003cli\u003eMyeloma Diagnostic Criteria\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular and Cytogenetic Risk Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eMonoclonal Protein Testing\u003c\/li\u003e\r\n \t\u003cli\u003eMyeloma-Related Bone Disease\u003c\/li\u003e\r\n \t\u003cli\u003eRenal Complications\u003c\/li\u003e\r\n \t\u003cli\u003eAnemia\u003c\/li\u003e\r\n \t\u003cli\u003eHypercalcemia\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Selection\u003c\/li\u003e\r\n \t\u003cli\u003eProteasome Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eImmunomodulatory Agents\u003c\/li\u003e\r\n \t\u003cli\u003eMonoclonal Antibody Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Immunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eBispecific Antibodies\u003c\/li\u003e\r\n \t\u003cli\u003eRelapsed and Refractory Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive Care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe topic highlights the importance of integrating disease biology, patient characteristics, and modern treatment approaches into clinical care.\r\n\u003ch2\u003eSession III – Coagulation and Hemostasis\u003c\/h2\u003e\r\n\u003ch3\u003eDisorders of Coagulation\u003c\/h3\u003e\r\n\u003cstrong\u003e10:30 AM – 11:15 AM\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Kenneth A. Bauer, MD\r\n\r\n\u003cstrong\u003eProfessor of Medicine, Harvard Medical School; Beth Israel Deaconess Medical Center\u003c\/strong\u003e\r\n\r\nThis session reviews clinically important disorders of coagulation and hemostasis.\r\n\r\nCoagulation abnormalities may result in excessive bleeding, thrombosis, or complex abnormalities involving several components of the hemostatic system.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCoagulation Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eHemostasis\u003c\/li\u003e\r\n \t\u003cli\u003eBleeding Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eThrombotic Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eInherited Coagulation Abnormalities\u003c\/li\u003e\r\n \t\u003cli\u003eAcquired Coagulation Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eCoagulation Factor Deficiencies\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Evaluation of Bleeding\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Evaluation of Thrombosis\u003c\/li\u003e\r\n \t\u003cli\u003eLaboratory Testing\u003c\/li\u003e\r\n \t\u003cli\u003eProthrombin Time\u003c\/li\u003e\r\n \t\u003cli\u003eActivated Partial Thromboplastin Time\u003c\/li\u003e\r\n \t\u003cli\u003eMixing Studies\u003c\/li\u003e\r\n \t\u003cli\u003eAnticoagulant Treatment Considerations\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Algorithms\u003c\/li\u003e\r\n \t\u003cli\u003eManagement Principles\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe presentation is relevant to clinicians involved in the assessment and treatment of patients with bleeding or thrombotic conditions.\r\n\u003ch2\u003eSession IV – Acute Leukemia\u003c\/h2\u003e\r\n\u003ch3\u003eAcute Myeloid Leukemia\u003c\/h3\u003e\r\n\u003cstrong\u003e11:15 AM – 12:00 PM\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Samah Nassereddine, MD\r\n\r\n\u003cstrong\u003eAssistant Professor of Medicine, The George Washington University, GW Cancer Center\u003c\/strong\u003e\r\n\r\nThis presentation focuses on acute myeloid leukemia, a heterogeneous hematologic malignancy characterized by abnormal proliferation of myeloid precursor cells.\r\n\r\nAdvances in molecular profiling and treatment approaches have increased the importance of accurate disease classification and risk-based management.\r\n\r\nImportant educational considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAcute Myeloid Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Presentation\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eAML Classification\u003c\/li\u003e\r\n \t\u003cli\u003eCytogenetic Abnormalities\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular Mutations\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Testing\u003c\/li\u003e\r\n \t\u003cli\u003eInduction Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eConsolidation Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eTargeted Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment of Older Adults\u003c\/li\u003e\r\n \t\u003cli\u003eRelapsed and Refractory AML\u003c\/li\u003e\r\n \t\u003cli\u003eHematopoietic Stem Cell Transplantation\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment-Related Complications\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive Care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe session supports understanding of current clinical approaches to AML diagnosis and management.\r\n\u003ch2\u003eSession V – Chronic Leukemia\u003c\/h2\u003e\r\n\u003ch3\u003eChronic Lymphocytic Leukemia\u003c\/h3\u003e\r\n\u003cstrong\u003e12:00 PM – 12:45 PM\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Imad A. Tabbara, MD, FACP\r\n\r\n\u003cstrong\u003eChief, Division of Hematology\/Oncology, DeCesaris Cancer Institute, Anne Arundel Medical Center; Clinical Professor of Medicine, The George Washington University\u003c\/strong\u003e\r\n\r\nThis session reviews contemporary developments in chronic lymphocytic leukemia.\r\n\r\nCLL is a mature B-cell malignancy with considerable variation in clinical presentation, disease progression, and treatment requirements.\r\n\r\nImportant clinical considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eChronic Lymphocytic Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eB-Cell Malignancies\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Presentation\u003c\/li\u003e\r\n \t\u003cli\u003eLymphocytosis\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Flow Cytometry\u003c\/li\u003e\r\n \t\u003cli\u003eDisease Staging\u003c\/li\u003e\r\n \t\u003cli\u003ePrognostic Biomarkers\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular Risk Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eObservation and Active Surveillance\u003c\/li\u003e\r\n \t\u003cli\u003eIndications for Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eTargeted Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eBTK Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eBCL-2 Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eMonoclonal Antibody Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eRelapsed and Refractory CLL\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment-Related Toxicities\u003c\/li\u003e\r\n \t\u003cli\u003eIndividualized Treatment Planning\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe presentation explores the evolving management of CLL and the role of risk-adapted therapy.\r\n\u003ch2\u003eSession VI – Lymphoid Malignancies\u003c\/h2\u003e\r\n\u003ch3\u003eLymphoma\u003c\/h3\u003e\r\n\u003cstrong\u003e1:45 PM – 2:45 PM\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Nina Delaney Wagner-Johnston, MD\r\n\r\n\u003cstrong\u003eDirector of Lymphoma Drug Development, Sidney Kimmel Comprehensive Cancer Center; Professor of Oncology, Johns Hopkins University School of Medicine\u003c\/strong\u003e\r\n\r\nThis session examines contemporary clinical approaches to lymphoma.\r\n\r\nLymphomas represent a diverse group of lymphoid malignancies requiring accurate pathological classification, staging, prognostic assessment, and disease-specific treatment.\r\n\r\nImportant discussion areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHodgkin Lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eNon-Hodgkin Lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eB-Cell Lymphomas\u003c\/li\u003e\r\n \t\u003cli\u003eT-Cell Lymphomas\u003c\/li\u003e\r\n \t\u003cli\u003eLymphoma Classification\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Presentation\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Biopsy\u003c\/li\u003e\r\n \t\u003cli\u003eHistopathology\u003c\/li\u003e\r\n \t\u003cli\u003eImmunophenotyping\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular Testing\u003c\/li\u003e\r\n \t\u003cli\u003eDisease Staging\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Selection\u003c\/li\u003e\r\n \t\u003cli\u003eImmunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eTargeted Therapies\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eRelapsed and Refractory Lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Toxicities\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Follow-Up\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe presentation addresses the importance of integrating disease subtype, patient characteristics, and evolving therapeutic options.\r\n\u003ch2\u003eSession VII – Bone Marrow Disorders\u003c\/h2\u003e\r\n\u003ch3\u003eBone Marrow Failure\u003c\/h3\u003e\r\n\u003cstrong\u003e2:45 PM – 3:45 PM\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Mrinal S. Patnaik, MD\r\n\r\n\u003cstrong\u003eProfessor of Internal Medicine, Division of Hematology, Mayo Clinic\u003c\/strong\u003e\r\n\r\nThis presentation reviews bone marrow failure and its diagnostic and therapeutic challenges.\r\n\r\nBone marrow failure syndromes may result in reduced production of red blood cells, white blood cells, platelets, or multiple blood cell lineages.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBone Marrow Failure Syndromes\u003c\/li\u003e\r\n \t\u003cli\u003eAplastic Anemia\u003c\/li\u003e\r\n \t\u003cli\u003eMyelodysplastic Neoplasms\u003c\/li\u003e\r\n \t\u003cli\u003eCytopenias\u003c\/li\u003e\r\n \t\u003cli\u003ePancytopenia\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Hypocellularity\u003c\/li\u003e\r\n \t\u003cli\u003eInherited Bone Marrow Failure\u003c\/li\u003e\r\n \t\u003cli\u003eAcquired Bone Marrow Failure\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Biopsy\u003c\/li\u003e\r\n \t\u003cli\u003eCytogenetic Testing\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular Testing\u003c\/li\u003e\r\n \t\u003cli\u003eDifferential Diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive Care\u003c\/li\u003e\r\n \t\u003cli\u003eImmunosuppressive Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eHematopoietic Stem Cell Transplantation\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Selection\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe session emphasizes a systematic approach to identifying causes of bone marrow dysfunction and developing appropriate management plans.\r\n\u003ch2\u003eClosing Session\u003c\/h2\u003e\r\n\u003ch3\u003eClosing Remarks | Adjournment\u003c\/h3\u003e\r\n\u003cstrong\u003e3:45 PM – 4:00 PM\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Robert S. Siegel, MD\r\n\r\nThe concluding session summarizes important developments in hematology and closes the educational program.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eMajor Topics Covered\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eGeorge Washington University Hematology Update Symposium 2026\u003c\/li\u003e\r\n \t\u003cli\u003eHematology Update\u003c\/li\u003e\r\n \t\u003cli\u003eMedical Oncology\u003c\/li\u003e\r\n \t\u003cli\u003eHematologic Malignancies\u003c\/li\u003e\r\n \t\u003cli\u003eNonmalignant Hematology\u003c\/li\u003e\r\n \t\u003cli\u003eMyeloproliferative Neoplasms\u003c\/li\u003e\r\n \t\u003cli\u003ePolycythemia Vera\u003c\/li\u003e\r\n \t\u003cli\u003eEssential Thrombocythemia\u003c\/li\u003e\r\n \t\u003cli\u003ePrimary Myelofibrosis\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Myelomonocytic Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular Hematology\u003c\/li\u003e\r\n \t\u003cli\u003eJAK2 Mutations\u003c\/li\u003e\r\n \t\u003cli\u003eCALR Mutations\u003c\/li\u003e\r\n \t\u003cli\u003eMPL Mutations\u003c\/li\u003e\r\n \t\u003cli\u003eMultiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003ePlasma Cell Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eMonoclonal Gammopathies\u003c\/li\u003e\r\n \t\u003cli\u003eMyeloma Risk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eCoagulation Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eBleeding Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eThrombotic Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eHemostasis\u003c\/li\u003e\r\n \t\u003cli\u003eCoagulation Testing\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Myeloid Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eAML Classification\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular Profiling\u003c\/li\u003e\r\n \t\u003cli\u003eTargeted Leukemia Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Lymphocytic Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eCLL Prognostic Markers\u003c\/li\u003e\r\n \t\u003cli\u003eBTK Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eBCL-2 Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eLymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eHodgkin Lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eNon-Hodgkin Lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eB-Cell Lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eT-Cell Lymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eLymphoma Immunotherapy\u003c\/li\u003e\r\n \t\u003cli\u003eCAR T-Cell Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Failure\u003c\/li\u003e\r\n \t\u003cli\u003eAplastic Anemia\u003c\/li\u003e\r\n \t\u003cli\u003eMyelodysplastic Neoplasms\u003c\/li\u003e\r\n \t\u003cli\u003eCytopenias\u003c\/li\u003e\r\n \t\u003cli\u003ePancytopenia\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Biopsy\u003c\/li\u003e\r\n \t\u003cli\u003eHematopoietic Stem Cell Transplantation\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-Based Hematology\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Hematology Guidelines\u003c\/li\u003e\r\n \t\u003cli\u003eRisk-Adapted Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive Hematologic Care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eMyeloproliferative Neoplasms and CMML\u003c\/h2\u003e\r\nMyeloproliferative neoplasms and chronic myelomonocytic leukemia represent important categories of clonal myeloid disease.\r\n\r\nAccurate evaluation may require integration of clinical findings, blood counts, bone marrow morphology, molecular abnormalities, and risk assessment.\r\n\r\nThe symposium includes a focused session addressing developments in these disorders.\r\n\r\nImportant clinical themes include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMyeloid Disease Classification\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular Diagnostics\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eThrombotic Complications\u003c\/li\u003e\r\n \t\u003cli\u003eDisease Progression\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Selection\u003c\/li\u003e\r\n \t\u003cli\u003eLong-Term Monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThese topics are especially relevant to hematologists managing patients with chronic myeloid neoplasms.\r\n\u003ch2\u003eMultiple Myeloma and Plasma Cell Disorders\u003c\/h2\u003e\r\nMultiple myeloma management has evolved substantially with the development of targeted agents, monoclonal antibodies, and cellular immunotherapies.\r\n\r\nThe curriculum provides an expert-led update on this important hematologic malignancy.\r\n\r\nRelevant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePlasma Cell Disease Diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular Risk Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eMyeloma-Related Organ Damage\u003c\/li\u003e\r\n \t\u003cli\u003eModern Treatment Approaches\u003c\/li\u003e\r\n \t\u003cli\u003eImmunomodulatory Therapies\u003c\/li\u003e\r\n \t\u003cli\u003eProteasome Inhibitors\u003c\/li\u003e\r\n \t\u003cli\u003eMonoclonal Antibodies\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging Immunotherapies\u003c\/li\u003e\r\n \t\u003cli\u003eRelapsed and Refractory Disease\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment-Related Toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe educational focus supports an integrated understanding of diagnosis, treatment planning, and supportive care.\r\n\u003ch2\u003eCoagulation and Hemostatic Disorders\u003c\/h2\u003e\r\nCoagulation disorders may cause clinically significant bleeding, thrombosis, or abnormalities detected during laboratory investigation.\r\n\r\nThe symposium addresses this broad field through an expert presentation on coagulation disorders.\r\n\r\nImportant clinical considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBleeding Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eThrombotic Risk\u003c\/li\u003e\r\n \t\u003cli\u003eHemostatic Testing\u003c\/li\u003e\r\n \t\u003cli\u003eInherited Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eAcquired Disorders\u003c\/li\u003e\r\n \t\u003cli\u003eLaboratory Interpretation\u003c\/li\u003e\r\n \t\u003cli\u003eDifferential Diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eAnticoagulation\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-Based Management\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe topic is relevant to hematologists, internists, hospitalists, and other clinicians evaluating patients with suspected hemostatic abnormalities.\r\n\u003ch2\u003eAcute Myeloid Leukemia\u003c\/h2\u003e\r\nAcute myeloid leukemia is a biologically diverse malignancy that requires timely diagnosis and individualized management.\r\n\r\nImportant aspects of clinical care include molecular classification, prognostic assessment, treatment selection, and management of complications.\r\n\r\nThe symposium includes an update dedicated to AML, providing a framework for reviewing recent diagnostic and therapeutic developments.\r\n\u003ch2\u003eChronic Lymphocytic Leukemia\u003c\/h2\u003e\r\nCLL treatment has undergone major changes with the introduction of targeted therapeutic strategies.\r\n\r\nManagement decisions may depend on symptoms, disease burden, prognostic abnormalities, comorbidities, patient preferences, and treatment-associated risks.\r\n\r\nThe course includes a dedicated CLL presentation emphasizing the evolving clinical management of this common mature B-cell malignancy.\r\n\u003ch2\u003eLymphoma Diagnosis and Management\u003c\/h2\u003e\r\nLymphoma includes multiple malignant lymphoid diseases with distinct clinical characteristics, biological behavior, and treatment approaches.\r\n\r\nAccurate diagnosis and management require coordination among hematologists, medical oncologists, hematopathologists, and other specialists.\r\n\r\nThe symposium provides a focused review of lymphoma and developments in treatment.\r\n\r\nThe educational emphasis includes disease classification, risk assessment, modern therapies, and management of challenging cases.\r\n\u003ch2\u003eBone Marrow Failure Syndromes\u003c\/h2\u003e\r\nBone marrow failure may cause anemia, neutropenia, thrombocytopenia, or pancytopenia.\r\n\r\nIts causes include acquired, inherited, immune-mediated, and clonal disorders.\r\n\r\nThe course addresses clinical and diagnostic considerations relevant to bone marrow failure.\r\n\r\nImportant principles include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eEvaluation of Cytopenias\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Morphology\u003c\/li\u003e\r\n \t\u003cli\u003eDifferential Diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eGenetic and Molecular Testing\u003c\/li\u003e\r\n \t\u003cli\u003eSupportive Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eDisease-Specific Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eTransplant Considerations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe session supports a structured understanding of complex bone marrow disorders.\r\n\u003ch2\u003eMolecular Diagnostics and Precision Hematology\u003c\/h2\u003e\r\nMolecular and cytogenetic testing increasingly contributes to disease classification, prognosis, and therapeutic decision-making in hematology.\r\n\r\nRelevant clinical applications include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eIdentification of Driver Mutations\u003c\/li\u003e\r\n \t\u003cli\u003eDisease Classification\u003c\/li\u003e\r\n \t\u003cli\u003ePrognostic Risk Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Selection\u003c\/li\u003e\r\n \t\u003cli\u003eMonitoring Disease Evolution\u003c\/li\u003e\r\n \t\u003cli\u003eRecognition of Therapeutic Targets\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe symposium's disease-focused sessions provide context for evaluating these developments across multiple hematologic disorders.\r\n\u003ch2\u003eEvidence-Based Clinical Decision-Making\u003c\/h2\u003e\r\nModern hematology requires integration of clinical findings, laboratory results, pathological examination, molecular information, and emerging therapeutic evidence.\r\n\r\nImportant clinical responsibilities include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eEstablishing Accurate Diagnoses\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluating Disease Severity\u003c\/li\u003e\r\n \t\u003cli\u003ePerforming Risk Stratification\u003c\/li\u003e\r\n \t\u003cli\u003eSelecting Appropriate Treatment\u003c\/li\u003e\r\n \t\u003cli\u003eMonitoring Treatment Response\u003c\/li\u003e\r\n \t\u003cli\u003eRecognizing Complications\u003c\/li\u003e\r\n \t\u003cli\u003eCoordinating Multidisciplinary Care\u003c\/li\u003e\r\n \t\u003cli\u003eApplying Current Clinical Evidence\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe \u003cstrong\u003eGW Hematology Update 2026\u003c\/strong\u003e program is designed to support the translation of scientific developments into practical clinical management.\r\n\u003ch2\u003eCourse Leadership\u003c\/h2\u003e\r\n\u003ch3\u003eRobert S. Siegel, MD\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eProfessor of Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eAssociate Center Director for Education and Training\u003c\/li\u003e\r\n \t\u003cli\u003eThe George Washington University, GW Cancer Center\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nDr. Siegel serves as the official Course Director of the 2026 Hematology Update Symposium.\r\n\u003ch2\u003eOfficial Faculty\u003c\/h2\u003e\r\nThe published 2026 program includes the following faculty:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eRobert S. Siegel, MD\u003c\/strong\u003e — The George Washington University\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAyalew Tefferi, MD\u003c\/strong\u003e — Mayo Clinic\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eKenneth Anderson, MD\u003c\/strong\u003e — Dana-Farber Cancer Institute \/ Harvard Medical School\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eKenneth A. Bauer, MD\u003c\/strong\u003e — Harvard Medical School \/ Beth Israel Deaconess Medical Center\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eSamah Nassereddine, MD\u003c\/strong\u003e — The George Washington University\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eImad A. Tabbara, MD, FACP\u003c\/strong\u003e — The George Washington University \/ Anne Arundel Medical Center\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eNina Delaney Wagner-Johnston, MD\u003c\/strong\u003e — Johns Hopkins University\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eMrinal S. Patnaik, MD\u003c\/strong\u003e — Mayo Clinic\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThese faculty members bring expertise in myeloid neoplasms, plasma cell disorders, coagulation, leukemia, lymphoma, and bone marrow disease.\r\n\u003ch2\u003eContinuing Medical Education\u003c\/h2\u003e\r\nThe George Washington University School of Medicine and Health Sciences designated the original live activity for a maximum of:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\u003cstrong\u003e7.00 AMA PRA Category 1 Credits™\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003e7.00 ABIM Maintenance of Certification Points\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe George Washington University School of Medicine and Health Sciences is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.\r\n\r\nEligible participants must satisfy the provider's attendance, completion, and evaluation requirements to claim applicable credits.\r\n\u003ch3\u003eImportant CME Notice\u003c\/h3\u003e\r\nThe credit amounts above apply only to eligible participation in the original George Washington University educational activity.\r\n\r\nPurchasing separately distributed educational materials from MedicalAmboss does not provide:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eGW CME Credits\u003c\/li\u003e\r\n \t\u003cli\u003eABIM MOC Points\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial Completion Certificates\u003c\/li\u003e\r\n \t\u003cli\u003eUniversity Conference Registration\u003c\/li\u003e\r\n \t\u003cli\u003eLive Symposium Attendance\u003c\/li\u003e\r\n \t\u003cli\u003eGW Educational Platform Access\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher Accounts\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial Online Recording Access\u003c\/li\u003e\r\n \t\u003cli\u003eOther Publisher-Hosted Benefits\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eWhy This Course Is Relevant\u003c\/h2\u003e\r\nThe \u003cstrong\u003eGeorge Washington University Hematology Update Symposium 2026\u003c\/strong\u003e addresses important developments in the diagnosis and treatment of blood disorders.\r\n\r\nHematology clinicians frequently evaluate patients with:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMyeloproliferative Neoplasms\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Myelomonocytic Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eMultiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eCoagulation Abnormalities\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Myeloid Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Lymphocytic Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eLymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Failure\u003c\/li\u003e\r\n \t\u003cli\u003eUnexplained Cytopenias\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThese conditions require accurate assessment, interpretation of clinical and laboratory evidence, appropriate risk stratification, and individualized treatment strategies.\r\n\r\nThe symposium combines disease-specific updates with perspectives from experienced hematology specialists.\r\n\r\nIts focused curriculum makes it particularly relevant for hematologists, medical oncologists, hematopathologists, internal medicine physicians, and other healthcare professionals involved in the care of patients with hematologic diseases.\r\n\u003ch2\u003eOfficial Program Reference and MedicalAmboss Purchase Scope\u003c\/h2\u003e\r\n\u003cstrong\u003eOfficial George Washington University Symposium:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/cme.smhs.gwu.edu\/hematology-and-oncology-best-practices-courses\/content\/2026-hematology-update-symposium\" data-rich-text-autolink=\"\"\u003ehttps:\/\/cme.smhs.gwu.edu\/hematology-and-oncology-best-practices-courses\/content\/2026-hematology-update-symposium\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eOfficial 2026 Course Agenda:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/cme.smhs.gwu.edu\/sites\/default\/files\/media\/2025-11\/2026%20Hematology%20Update%20Symposium%20Course%20Syllabus.pdf\" data-rich-text-autolink=\"\"\u003ehttps:\/\/cme.smhs.gwu.edu\/sites\/default\/files\/media\/2025-11\/2026%20Hematology%20Update%20Symposium%20Course%20Syllabus.pdf\u003c\/a\u003e\r\n\r\nThe official references describe the original conference, including the scheduled sessions, faculty, accreditation, venue, and participation arrangements.\r\n\r\nThey do not establish the exact inventory of digital files available through a separately distributed MedicalAmboss listing.\r\n\r\n\u003cstrong\u003eMedicalAmboss File Scope:\u003c\/strong\u003e This listing describes the educational subject matter for reference. Provider registration, live attendance, streaming-platform access, CME or other credit, certificates, memberships, apps, accounts, and publisher-hosted extras are not included unless explicitly listed as store files.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eShort Description\u003c\/h2\u003e\r\n\u0026lt;div style=\"border:2px solid #1677b8;border-radius:10px;padding:16px;background:#f7fbfe;\"\u0026gt;\r\n\r\n\u003cstrong\u003eGeorge Washington University Hematology Update Symposium 2026\u003c\/strong\u003e provides a comprehensive, evidence-based update on malignant and nonmalignant hematology, featuring leading experts from GW Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Harvard Medical School, and Johns Hopkins University.\r\n\r\nThe February 28, 2026 symposium covers myeloproliferative neoplasms, chronic myelomonocytic leukemia, multiple myeloma, coagulation disorders, acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma, and bone marrow failure.\r\n\u003ch3\u003eTopics\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWelcome- Siegel RS\u003c\/li\u003e\r\n \t\u003cli\u003eMyeloproliferative Neoplasms\u003c\/li\u003e\r\n \t\u003cli\u003eMultiple Myeloma\u003c\/li\u003e\r\n \t\u003cli\u003eDisorders of Coagulation\u003c\/li\u003e\r\n \t\u003cli\u003eAcute Myeloid Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Lymphocytic Leukemia\u003c\/li\u003e\r\n \t\u003cli\u003eLymphoma\u003c\/li\u003e\r\n \t\u003cli\u003eBone Marrow Failure\u003c\/li\u003e\r\n \t\u003cli\u003eClosing Adjournment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv class=\"medicalamboss-related-resources\"\u003e\u003c\/div\u003e\r\n\u003c!-- MAA_RELATED_RESOURCES_END --\u003e","brand":"Amboss","offers":[{"title":"Default Title","offer_id":67967781011610,"sku":"MED-AMB10535","price":25.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/macs-0efe51bcb5-50425-50434-80602180e5daa375fa23.jpg?v=1793059368","url":"https:\/\/ambosscourse.com\/products\/wc-0efe51bcb5f34c14-50425","provider":"Amboss","version":"1.0","type":"link"}